GSK’s Benlysta shows sustained disease control in study

19th June 2017 Uncategorised 0

Adding GSK’s Benlysta to standard of care in patients with lupus prolonged control of disease activity, according to newly-released findings of a 10-year continuation study.

More: GSK’s Benlysta shows sustained disease control in study
Source: News